| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.11. | Capricor, NextCure reveal recent layoffs as they gear up for approval decision, merger | ||
| 11.11. | Abbott nabs FDA approval, CE Mark for implantable cardioverter-defibrillator lead | ||
| 10.11. | Beam's sickle cell therapy results tee up potential Casgevy, Lyfgenia showdown | ||
| 10.11. | PepGen's stock doubles as midphase muscle dystrophy data wow analysts | ||
| 10.11. | AstraZeneca buys partner Omniose for bacterial vaccine technology | ||
| 10.11. | 'Flying blind': Why experts fear Treasury's China biotech investment crackdown will backfire | ||
| 10.11. | Mirum scores again in hepatitis D phase 3, setting the stage for brelovitug's FDA run | ||
| 10.11. | AbCellera becomes latest biotech to abandon dream of developing OX40 drug | ||
| 10.11. | Coherus shrinks headcount 30% to narrow focus of cancer combo | ||
| 09.11. | Merck's MASH hopeful efinopegdutide wins in mid-stage study | ||
| 09.11. | When China Fits a Global Clinical Development Strategy | ||
| 09.11. | Recent Lisata prize Marea touts 'exciting' lipid disorder phase 2 win, mulls obesity potential | ||
| 09.11. | J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depression | ||
| 09.11. | Zura scraps hidradenitis suppurativa program after phase 2 miss, sinking stock | ||
| 09.11. | Spruce spins out preclinical endocrinology program into newly formed Adrenyx | ||
| 09.11. | AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test | ||
| 09.11. | Sanofi-backed Windward Bio breezes toward $204M IPO to fund respiratory pipeline from China | ||
| 09.11. | Advanced Analytics Help Reduce Control Animal Use While Preserving Scientific Rigor | ||
| 09.11. | Kyorin pens $140M deal for Japan rights to Edesa's phase 3 respiratory drug | ||
| 09.11. | Faeth's phase 2 data power oral combo forward in cancer targeted by ADC heavyweights | ||
| 09.11. | Vir's phase 3 hepatitis delta win fuels push to eclipse Gilead | ||
| 09.11. | Argenx inks $1.15B Unnatural Products buyout to expand in oral peptides | ||
| 09.11. | Valneva sees LimmaTech vaccine reduce Shigella infections in phase 2 test | ||
| 07.11. | Novartis' Lp(a) drug shows zero benefit, casting shadow over Amgen and Lilly programs | ||
| 06.11. | Looking Beyond the First Answer Towards Delivering Impact |